8-K: Bausch Health's Debt Exchange Offer Oversubscribed

Bausch Health Companies Inc. announced early results for its debt exchange offer, with tendered notes exceeding the maximum new notes amount.

Summary

• Bausch Health announced early results for its exchange offers for outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028.
• The offers are to exchange these existing notes for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, issued by its indirect wholly-owned subsidiary 1261229 B.C. Ltd.
• As of the early tender time (December 8, 2025, 5:00 p.m. New York City time), an aggregate principal amount of $2,690,016,000 of existing notes had been validly tendered.
• This tendered amount significantly exceeds the maximum new notes amount of $1.6 billion, indicating the offer is oversubscribed.
• Approximately $1,600 million of New Notes are expected to be issued, subject to proration and other terms outlined in the confidential exchange offer memorandum dated November 24, 2025.
• Withdrawal rights for the offers expired on December 8, 2025, and no further withdrawals are permitted.
• Any existing notes tendered after the early tender time but prior to the expiration time will not be accepted due to the oversubscription.

Sentiment

Score: 7

Explanation: The oversubscription of the exchange offer is a positive sign, indicating strong market confidence in the new debt issuance and the company's ability to manage its debt maturity profile. While the new notes carry a higher interest rate, successfully extending maturities is a crucial step in debt management.

Positives

• The exchange offer was significantly oversubscribed, with $2.69 billion in existing notes tendered against a maximum issuance of $1.6 billion in new notes, indicating strong investor interest in the new 10.00% Senior Secured Notes due 2032.
• Successful execution of the exchange offer will allow Bausch Health to extend the maturity profile of a portion of its debt from 2028 to 2032.

Negatives

• The new notes carry a higher interest rate (10.00%) compared to the 4.875% notes, which will increase interest expense for the portion of debt exchanged from the lower rate.
• The company is exchanging 2028 notes for 2032 notes, indicating a need to manage upcoming debt maturities.

Risks

• The New Notes will not be registered under the Securities Act or any state securities laws, limiting their marketability to certain eligible holders.
• The New Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including the completion and timing of the Offers.

Future Outlook

The company expects to issue approximately $1.6 billion of new 10.00% Senior Secured Notes due 2032, extending the maturity of a portion of its debt. The settlement date is anticipated within three business days following the expiration time of December 23, 2025.

Management Comments

• The Company cannot assure you that the Offers will be completed on schedule, or at all.

Industry Context

This exchange offer is a common strategy for companies with significant debt loads to proactively manage their maturity schedules, especially in a rising interest rate environment or when seeking to optimize their capital structure. By extending maturities, Bausch Health aims to reduce near-term refinancing risk, a trend seen across industries with high leverage. The higher interest rate on the new notes reflects current market conditions and the company's credit profile.

Comparison to Industry Standards

• The oversubscription of the exchange offer suggests that the 10.00% yield on the new 2032 notes was attractive to institutional investors, indicating a market appetite for Bausch Health's debt at this coupon, which is comparable to other high-yield pharmaceutical or healthcare companies managing significant debt.
• The strategy of extending maturities through exchange offers is a standard debt management practice, similar to actions taken by companies like Mallinckrodt or Endo International in the specialty pharma sector, which have also faced substantial debt burdens and sought to push out maturities.
• The proration due to oversubscription is a positive sign, demonstrating strong demand for the new debt instrument, which can be contrasted with less successful exchange offers where companies struggle to meet minimum tender conditions.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced near-term refinancing risk and improved debt maturity profile, but increased interest expense could impact future earnings.
• Existing Noteholders (tendered): Those who tendered successfully will exchange their 2028 notes for 2032 notes with a 10.00% coupon, potentially securing a higher yield (for 4.875% holders) and longer maturity.
• Existing Noteholders (not tendered or prorated): Will retain their existing notes, which may see price fluctuations based on the success of the exchange and the company's overall debt strategy.
• Creditors: The company's debt maturity profile is extended for a portion of its debt, potentially improving its liquidity position in the near term.

Next Steps

• The exchange offers will expire at 5:00 p.m., New York City time, on December 23, 2025.
• The settlement date for the new notes is expected within three business days following the expiration time.

Key Dates

Recommendation

The successful oversubscription of the debt exchange offer is a positive development for Bausch Health, demonstrating market confidence in its ability to manage its substantial debt load by extending maturities. This reduces near-term refinancing risk, which is generally favorable for the stock. However, the higher interest rate on the new notes will increase future interest expenses, potentially offsetting some of the benefits. Given the ongoing challenges of high leverage and the increased cost of debt, a 'hold' recommendation is appropriate. Investors should monitor the company's overall debt reduction efforts and operational performance, especially in its core pharmaceutical segments, to assess long-term value.

Keywords

Bausch Health, BHC, Exchange Offer, Senior Secured Notes, Debt Refinancing, Debt Exchange, Corporate Debt, Fixed Income, Securities Exchange Commission, 8-K Filing, Pharmaceuticals, Bausch + Lomb